

DAFTAR PUSTAKA

- Balasubramanian S, Eckert RL. Keratinocyte proliferation, differentiation, and apoptosis – differential mechanisms of regulation by curcumin, EGCG and apigenin. *Toxicol Appl Pharmacol*. 2017;224:214–219.
- Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, Adame S, Massey RJ, Wood GS, Longley BJ, Mousa SA, Mukhtar H. Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. *Int J Nanomedicine*. 2018;13:4189-4206.
- Crow JM. Therapeutics: Silencing psoriasis. *Nature*. 2012;492:S58–S59.
- Czarnowicki, T.; Krueger, J.G.; Guttman-Yassky, E. Skin barrier and immune dysregulation in atopic dermatitis: An evolving story with important clinical implications. *J. Allergy Clin. Immunol. Pract*. 2014, 2, 371–379.
- Dhatwalia, S. K., Kumar, M., & Dhawan, D. K. *Role of EGCG in Containing the Progression of Lung Tumorigenesis – A Multistage Targeting Approach. Nutrition and Cancer*, 2018;70(3), 334–349.
- Dubois Declercq S, Pouliot R. Promising new treatments for psoriasis. *Scientific World Journal*. 2013;2013:980419.
- Ellis LZ, Liu W, Luo Y, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1 β secretion. *Biochem Biophys Res Commun*. 2011;414:551–556
- Frias I, Neves AR, Pinheiro M, Reis S. Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation. *Drug Des Devel Ther*. 2016;10:3519-3528.
- Granja A, Frias I, Neves AR, Pinheiro M, Reis S. Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems. *Biomed Res Int*. 2017;2017:5813793.

- Hoffjan S, Stemmler S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. *Br J Dermatol.* 2010;157:441–449.
- Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. *Am J Clin Dermatol.* 2016;17:87–97.
- Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. *Nature.* 2013;445:866–873.
- Mahmoodi NO, Ghavidast A, Amirmahani N. A comparative study on the nanoparticles for improved drug delivery systems. *J Photochem Photobiol B.* 2016;162:681–693.
- Matsui, T.; Amagai, M. Dissecting the formation, structure and barrier function of the stratum corneum. *Int. Immunol.* 2015, 27, 269–280.
- Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of Psoriasis and Development of treatment. *J.Dermatol* 2018 Mar;45(3):264-272.
- Parisi R, Symmons DPM, Griffith CEM, Ashcroft DM. The Identification and Management of Psoriasis and Associated Comorbidity project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *Journal of Investigative Dermatology.* 2013;133:377–85.
- Singh, B. N., Shankar, S., & Srivastava, R. K. *Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochemical Pharmacology, 2011;82(12), 1807–1821.*
- Tyagi N, Ranjit De, Jakob Begun, Amirali Popat, Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles, *International Journal of Pharmaceutics.* 2016, 220-227.
- Wolff K, Johnson R. Psoriasis. Dalam Wolff K., Johnson R.A. Fitzpatrick's color atlas and synopsis of clinical dermatology. Ed. 6. New York : Mc Graw Hill; 2009, 53-71.
- Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. *J Cutan Med Surg.* 2013;17:6–12.